Company Overview and News


Add ONCE
to your dashboard

Headline News

New drugs recast $10 bln haemophilia market as Sanofi swoops in

1h reuters
LONDON (Reuters) - Sanofi is placing a big bet on the $10 billion-a-year hemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder. (23-0)

Sector Report: How The Pressure On Generic Drugs Is Creating Tailwind For Branded Molecules

2018-01-19 seekingalpha
"If you hope to have more money tomorrow than you have today, you've got to put a chunk of your assets into stocks. Sooner or later, a portfolio of stocks or stock mutual funds will turn out to be a lot more valuable than a portfolio of bonds or CDs or money-market funds." - Peter Lynch (124-0)

3 Biotech Stocks Start Healthy in ’18: Will the Rally Last?

2018-01-18 investorplace
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Last year, the industry benefited from a number of FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strength in some legacy products. There were some first-time approvals for innovative/game-changing treatment options. (78-0)

Your Daily Pharma Scoop: Juno Surges On Takeover Rumors, AEterna Zentaris Achieves Another Milestone, Spark Granted ODD

2018-01-18 seekingalpha
Juno shares surged on WSJ report that Celgene is in talks to acquire the CAR-T company. (193-1)

Spark Therapeutics: Challenges Posed By Success

2018-01-17 seekingalpha
The leading product LUXTURNA was signed off by FDA as the world’s first gene therapy to treat patients with biallelic RPE65-mediated inherited retinal disease (IRD). (83-0)

BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

2018-01-17 zacks
Chicago, IL – Jan 17, 2018 – Zacks Equity Research highlights BlackRock (BLK - Free Report) as the Bull of the Day, Pier One Imports (PIR - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAlkermes plc( (ALKS - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) and Agenus Inc. (AGEN - Free Report) . (166-4)

Abeona Therapeutics: The Upcoming Neurocognitive Catalyst

2018-01-16 seekingalpha
Abeona is an early-stage biotechnology company that focuses on developing novel gene therapies for rare diseases. (34-1)

3 Biotech Stocks Start Healthy in '18: Will the Rally Last?

2018-01-16 zacks
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Last year, the industry benefited from a number of FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strength in some legacy products. There were some first-time approvals for innovative/game-changing treatment options. (89-1)

Why The NBA's Global Business Is On The Rise

2018-01-15 zacks
Welcome to the latest episode of Full-Court Finance, the podcast from Zacks Investment Research focused on the intersection of sports, business, and the stock market. On this week’s episode, we explore the growing international business of the NBA at the halfway point of the 2017-18 season. (92-0)

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-13 in.reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Here's what people talked about at JP Morgan's health-care conference

2018-01-12 cnbc
The biggest health-care investing conference of the year has come to an end, but the ideas discussed will continue to play out this year. (2-0)

Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-12 reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Spark's price for Luxturna blindness gene therapy too high: ICER - Channel NewsAsia

2018-01-12 channelnewsasia
REUTERS: The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday. (9-0)

Drugmakers see a pricing blueprint in an US$850,000 gene therapy - Channel NewsAsia

2018-01-12 channelnewsasia
SAN FRANCISCO: Global drugmakers are looking to a tiny biotech's US$850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

2018-01-12 reuters
(Reuters) - The proposed price for Spark Therapeutics Inc’s groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday. (2-0)

CUSIP: 84652J103